View by Specialty

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

Esophagus News

SPONSORED CONTENT
Save
SPONSORED CONTENT
February 12, 2024
2 min read
Save

Takeda’s Eohilia rebounds to win FDA approval as ‘first and only’ oral therapy for EoE

Takeda’s Eohilia rebounds to win FDA approval as ‘first and only’ oral therapy for EoE

The FDA has approved Takeda Pharmaceuticals’ Eohilia as the “first and only oral therapy” for treatment of eosinophilic esophagitis in patients aged 11 years or older, according to a press release.

SPONSORED CONTENT
February 07, 2024
1 min read
Save

Cyted snags FDA 510(k) clearance for non-endoscopic esophageal precancer test

Cyted snags FDA 510(k) clearance for non-endoscopic esophageal precancer test

The FDA granted 510(k) clearance to Cyted’s EndoSign, a non-endoscopic capsule sponge device intended to gather pan-esophageal samples for early detection of esophageal cancer as well as other conditions, according to a company release.

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

SPONSORED CONTENT
February 05, 2024
3 min read
Save

Immune-resetting peptide gets orphan drug designation for eosinophilic esophagitis

Immune-resetting peptide gets orphan drug designation for eosinophilic esophagitis

The FDA has granted an orphan drug designation to ’1104 from Revolo Biotherapeutics, a first-in-class immune-resetting peptide designed to treat eosinophilic esophagitis, according to a press release.

SPONSORED CONTENT
February 02, 2024
2 min read
Save

Q&A: Improved outcomes anticipated with dupilumab for children with EoE

Q&A: Improved outcomes anticipated with dupilumab for children with EoE

Treatment options for children with eosinophilic esophagitis have expanded with the FDA’s approval of dupilumab for those aged 1 to 11 years who weigh at least 15 kg, according to a press release.

SPONSORED CONTENT
January 26, 2024
2 min read
Save

FDA approves dupilumab for children with eosinophilic esophagitis

FDA approves dupilumab for children with eosinophilic esophagitis

The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in children aged 1 to 11 years who weigh at least 15 kg, according to a press release.

SPONSORED CONTENT
November 27, 2023
2 min read
Save

On-demand vonoprazan may replace daily therapy for nonerosive reflux disease

On-demand vonoprazan may replace daily therapy for nonerosive reflux disease

Researchers reported that on-demand vonoprazan may be a “reasonable alternative” to daily therapy for heartburn, after demonstrating complete and sustained relief of more heartburn episodes than placebo.

SPONSORED CONTENT
November 10, 2023
2 min read
Save

Etrasimod 2 mg reduces peak eosinophil count at week 16, improves symptom severity

Etrasimod 2 mg reduces peak eosinophil count at week 16, improves symptom severity

VANCOUVER, British Columbia — Once-daily etrasimod 2 mg was well-tolerated and reduced peak eosinophil count at week 16 in patients with eosinophilic esophagitis, according to data presented at the ACG Annual Scientific Meeting.

SPONSORED CONTENT
November 09, 2023
3 min read
Save

Dupilumab sustains histologic, endoscopic improvement up to 1 year in children with EoE

Dupilumab sustains histologic, endoscopic improvement up to 1 year in children with EoE

VANCOUVER, British Columbia — High-dose dupilumab achieved significant improvements in histologic and endoscopic measures through 52 weeks in children aged 1 to 11 years with eosinophilic esophagitis, according to late-breaking data.

SPONSORED CONTENT
November 02, 2023
2 min read
Save

Voquezna back on track with FDA approval for erosive esophagitis, heartburn relief

Voquezna back on track with FDA approval for erosive esophagitis, heartburn relief

The FDA has approved Phathom Pharmaceuticals’ Voquezna tablets 10 mg and 20 mg to treat erosive esophagitis, or erosive gastroesophageal reflux disease, and alleviate heartburn associated with the disease, noted a company release.

SPONSORED CONTENT
October 23, 2023
2 min read
Save

World Trade Center firefighters using inhaled medication, steroids at risk for GERD

World Trade Center firefighters using inhaled medication, steroids at risk for GERD

HONOLULU — Use of short-acting beta agonists and steroids each raised the likelihood for gastroesophageal reflux disease among firefighters exposed to 9/11 particulate matter, according to a presentation at the CHEST Annual Meeting.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails